Skip to main navigation Skip to search Skip to main content

Randomized, Open-label, Phase 3 Study of Prostate-specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG160 vs Standard of Care in mCRPC

Project: Research

Project Details

StatusFinished
Effective start/end date10/1/21 → 12/31/25

Funding

  • Amgen Incorporated: $5,000.00